Source comparison
CJC-1295 No DAC vs Modified DAC: Half-Life Trade-Offs
Plasma Half-Life ~30 minutes 6–8 days No-DAC clears rapidly; DAC persists across multiple circadian cycles Dosing Frequency 1–3x daily (pulse timing) 1–2x weekly No-DAC requires intentional circadian alignment; DAC offers convenience GH Secretion Pattern Pulsa
This comparison does not assign a generated winner or score.
- Plasma Half-Life
- ~30 minutes
- 6–8 days
- No-DAC clears rapidly; DAC persists across multiple circadian cycles
- Dosing Frequency
- 1–3x daily (pulse timing)
- 1–2x weekly
- No-DAC requires intentional circadian alignment; DAC offers convenience
- GH Secretion Pattern
- Pulsatile amplification (preserves natural rhythm)
- Tonic elevation (sustained baseline increase)
- No-DAC mimics endogenous GHRH bursts; DAC creates non-physiological steady state
- Receptor Desensitisation Risk
- Low (transient agonism allows resensitisation)
- Moderate to high (chronic receptor occupancy downregulates density)
- No-DAC maintains receptor sensitivity long-term; DAC shows diminishing returns after 8–12 weeks
- Co-Administration Synergy
- Strong synergy with GHRP-2, GHRP-6, ipamorelin (stacked pulses)
- Weaker synergy (tonic GHRH + pulsatile GHRP creates mixed signaling)
- No-DAC allows precise pulse stacking; DAC creates overlapping tonic + pulsatile signals that may reduce peak amplitude
- Ideal Research Application
- Circadian rhythm preservation, receptor sensitivity studies, pulsatile endocrinology models
- Sustained GH elevation studies, convenience-focused protocols
- No-DAC is the physiological choice for long-term protocols; DAC suits short-term convenience studies where receptor downregulation is acceptable
- The trade-off is precision versus convenience. CJC-1295 with DAC (Drug Affinity Complex modification) extends half-life to 6–8 days by preventing enzymatic degradation and renal clearance. That sounds advantageous until you consider what sustained GHRH receptor agonism does to feedback loops. Hypothalamic somatostatin (growth hormone-inhibiting hormone) is released in response to elevated GH. It's the brake pedal that terminates each natural pulse. Tonic GH elevation from DAC versions triggers sustained somatostatin release, which progressively blunts pituitary response. Studies on continuous GHRH infusion show receptor desensitisation becomes measurable within 7–10 days and plateaus GH output despite ongoing stimulation.
- CJC-1295 no DAC avoids this by clearing between doses. Somatotroph GHRH receptors have time to resensitise. Hypothalamic feedback loops reset. The next dose triggers the same magnitude response as the first dose. Receptor density remains stable across months of use. This is why long-term peptide protocols in performance and longevity research overwhelmingly favour no-DAC formulations despite the dosing frequency inconvenience.